Epidemiology and Clinical Presentations of the Four Human Coronaviruses 229E, HKU1, NL63, and OC43 Detected over 3 Years Using a Novel Multiplex Real-Time PCR Method by Gaunt, Eleanor R et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epidemiology and Clinical Presentations of the Four Human
Coronaviruses 229E, HKU1, NL63, and OC43 Detected over 3
Years Using a Novel Multiplex Real-Time PCR Method
Citation for published version:
Gaunt, ER, Hardie, A, Claas, EC, Simmonds, P & Templeton, KE 2010, 'Epidemiology and Clinical
Presentations of the Four Human Coronaviruses 229E, HKU1, NL63, and OC43 Detected over 3 Years
Using a Novel Multiplex Real-Time PCR Method' Journal of Clinical Microbiology, vol. 48, no. 8, pp. 2940-7.
DOI: 10.1128/JCM.00636-10
Digital Object Identifier (DOI):
10.1128/JCM.00636-10
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Clinical Microbiology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2010, p. 2940–2947 Vol. 48, No. 8
0095-1137/10/$12.00 doi:10.1128/JCM.00636-10
Copyright © 2010, American Society for Microbiology. All Rights Reserved.
Epidemiology and Clinical Presentations of the Four Human
Coronaviruses 229E, HKU1, NL63, and OC43 Detected over 3
Years Using a Novel Multiplex Real-Time PCR Method
E. R. Gaunt,1 A. Hardie,2 E. C. J. Claas,3 P. Simmonds,1 and K. E. Templeton2*
Centre for Infectious Diseases, University of Edinburgh, Summerhall, Edinburgh EH9 1QH, United Kingdom1; Department of
Virology, Royal Infirmary of Edinburgh, 51 Little France Crescent, Old Dalkeith Road, Edinburgh EH16 4SA, United Kingdom2; and
Department of Medical Microbiology, Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands3
Received 25 March 2010/Returned for modification 14 May 2010/Accepted 10 June 2010
Four human coronaviruses (HCoV-229E, HCoV-HKU1, HCoV-NL63, and HCoV-OC43) are associated with
a range of respiratory outcomes, including bronchiolitis and pneumonia. Their epidemiologies and clinical
characteristics are poorly described and are often reliant on case reports. To address these problems, we
conducted a large-scale comprehensive screening for all four coronaviruses by analysis of 11,661 diagnostic
respiratory samples collected in Edinburgh, United Kingdom, over 3 years between July 2006 and June 2009
using a novel four-way multiplex real-time reverse transcription-PCR (RT-PCR) assay. Coronaviruses were
detected in 0.3 to 0.85% of samples in all age groups. Generally, coronaviruses displayed marked winter
seasonality between the months of December and April and were not detected in summer months, which is
comparable to the pattern seen with influenza viruses. HCoV-229E was the exception; detection was confined
to the winter of 2008 and was sporadic in the following year. There were additional longer-term differences in
detection frequencies between seasons, with HCoV-OC43 predominant in the first and third seasons and
HCoV-HKU1 dominating in the second (see Results for definitions of seasons). A total of 11 to 41% of
coronaviruses detected were in samples testing positive for other respiratory viruses, although clinical pre-
sentations of coronavirus monoinfections were comparable to those of viruses which have an established role
in respiratory disease, such as respiratory syncytial virus, influenza virus, and parainfluenza viruses. The novel
multiplex assay for real-time pan-coronavirus detection enhances respiratory virus diagnosis, overcomes
potential diagnostic problems arising through seasonal variation in coronavirus frequency, and provides novel
insights into the epidemiology and clinical implications of coronaviruses.
Four human coronaviruses (human coronavirus 229E [HCoV-
229E], HCoV-HKU1, HCoV-NL63, and HCoV-OC43) are as-
sociated with a range of respiratory symptoms, including high-
morbidity outcomes such as pneumonia and bronchiolitis (26,
31, 35). Specifically, HCoV-NL63 has been associated with
croup (33) and HCoV-HKU1 with febrile convulsion (18).
Coronaviruses are frequently codetected with other respiratory
viruses, particularly with human respiratory syncytial virus
(HRSV) (17). Whether coronaviruses contribute to disease
severity in such coinfections is currently unclear. Other coro-
naviruses infecting humans include human enteric coronavirus,
which is closely related to HCoV-OC43 and is associated with
necrotizing enterocolitis and gastroenteritis (10, 27).
Coronaviruses are globally distributed (7, 32, 34, 38), al-
though there are differences in the frequency of detection of
the four viruses in different parts of the world at different times
(6, 11, 15, 16, 22, 28, 29). Longitudinal studies of coronavirus
epidemiology are lacking in the literature and are restricted to
descriptions representing a maximum of 1 year for all four
respiratory coronaviruses or 2 years for three coronaviruses (9,
17, 18). This inevitably makes direct comparisons of the coro-
naviruses difficult with respect to their epidemiologies, clinical
presentations, and etiological roles in respiratory disease.
To directly address this situation, we conducted a large-scale
survey of the incidences and epidemiological and clinical cor-
relations of the four coronaviruses detected among 11,661 re-
spiratory samples collected over a 3-year study period in Ed-
inburgh, United Kingdom. Clinical presentations of study
subjects infected with each of the coronaviruses were directly
compared, and their roles in pediatric and adult respiratory
disease were assessed.
MATERIALS AND METHODS
Sample collection. Respiratory samples collected at hospital and primary care
settings in southeast Scotland are referred to the Royal Infirmary of Edinburgh
(RIE) Specialist Virology Centre (SVC) for routine respiratory virus screening.
Referral of samples to the RIE SVC is done by patient assessment following
established clinical protocols. Samples were labeled with anonymous identifiers
and deposited in the SVC sample archive prior to testing. Samples were stored
at 80°C. A range of sample types are referred, including bronchial, nasal,
nasopharyngeal (the most common category), oral, and tracheal samples.
A total of 11,661 respiratory samples from 7,383 patients referred to the RIE
SVC between July 2006 and June 2009 were labeled with anonymous identifiers
and archived with approval from the Lothian Regional Ethics Committee (08/
S11/02/2). Stored data included age band, recorded clinical information, referral
source, month of sample collection, and results of routine virological testing of
the sample. As part of routine virological screening, RNA and DNA were
extracted using a Qiagen BioRobot MDx system and screened for HRSV, ade-
novirus (AdV), parainfluenza viruses 1, 2, and 3 (PIV-1 to PIV-3) and influenza
A and B viruses by the use of multiplex one-step real-time reverse transcription-
PCR (RT-PCR) (14, 30). Extracted nucleic acids were stored at 20°C.
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Clinical data interpretation. Clinical symptoms recorded on sample referral
forms were categorized into seven groups—immunocompromised, chronic re-
spiratory condition, lower respiratory tract infection (LRTI), upper respiratory
tract infection (URTI), other, none, and no data. Inevitably, some samples were
assignable to two or more categories, and so categories were treated in a hier-
archical manner, whereby samples were preferentially assigned to categories in
the order listed above. The immunocompromised group included patients with
carcinoma and transplant patients. Coryza, cough, and sore throat were classified
as URTIs. Bronchitis, bronchiolitis, pneumonia, influenza-like illness, and sus-
pected HRSV infection were classified as LRTIs. Samples for which no clinical
data were available were excluded from the clinical data analysis. Chronic re-
spiratory conditions included asthma and cystic fibrosis. The “other” group
included symptoms which may be associated with but are not restricted to
infection with respiratory pathogens, e.g., pyrexia, neurological and gastrointes-
tinal symptoms, and requirement for ventilation. The “none” group included
symptoms or data not associated with respiratory tract infection, e.g., rash or
urinary tract infection.
Sensitivity of real-time multiplex PCR for coronavirus detection. RNA tran-
scripts of the four coronaviruses were used as standards to determine assay
sensitivity. HCoV-229E, HCoV-NL63, and HCoV-OC43 cDNAs (processed us-
ing nucleic acid extraction and reverse transcription as described below) were
subjected to single-round real-time PCR as described below. PCR products were
cloned into PCR2.1 T/A cloning vector (Invitrogen, Paisley, United Kingdom)
according to the manufacturer’s instructions for transformation of electrocom-
petent Escherichia coli. Cultures were plated on agar containing lactose and
kanamycin (50 g/ml) and grown overnight at 37°C. Blue colonies were picked,
and successful transformation was confirmed by sequence analysis. Products
were purified using a Qiagen (Crawley, United Kingdom) Qiaprep spin miniprep
kit and were transcribed in vitro using a Promega (Southampton, United King-
dom) T7 RiboMAX large-scale RNA production system.
HCoV-HKU1-positive cDNA underwent PCR, using a sense primer incorpo-
rating a T7 promoter site for DNA amplification. DNA was cleaned using a
Qiagen (Crawley, United Kingdom) QIAquick PCR purification kit and tran-
scribed in vitro using a Promega (Southampton, United Kingdom) T7 RiboMAX
large-scale RNA production system. Reactions were terminated and RNAs pu-
rified using a Qiagen (Crawley, United Kingdom) RNeasy mini-kit.
Coronavirus RNA transcript purity and concentration were established using
a nanodrop spectrophotometer (Nanodrop Technologies). The sensitivity of the
multiplex assay was established for each coronavirus by testing transcripts of
known concentrations serially diluted in Tris-EDTA (TE) buffer. Cycle threshold
(CT) values for each set of transcripts were established using multiplex and
monoplex assays to detect any loss of sensitivity resulting from multiplexing.
Specificity of real-time multiplex PCR for coronavirus detection. A panel of
respiratory viruses and bacteria commonly found in the respiratory tract was used
to determine the specificity of the multiplex PCR. Nucleic acids were extracted
from samples positive for influenza A virus, influenza B virus, HRSV, PIV-1 to
PIV-4, AdV type 5, human metapneumovirus, rhinoviruses 1b and 16, echovirus
7, mumps virus, measles virus, Bordetella bronchiseptica, Bordetella parapertussis,
Bordetella pertussis, Burkholderia cepacia, Chlamydia pneumoniae, Haemophilus
influenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneu-
moniae, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneu-
moniae and tested by multiplex PCR under the conditions described below.
Real-time multiplex PCR for coronavirus detection. Nucleic acids were pooled
in groups of 10. Pools were screened for HCoV-229E, HCoV-HKU1, HCoV-
NL63, and HCoV-OC43 by one-step multiplex RT-PCR using a Qiagen (Craw-
ley, United Kingdom) one-step RT-PCR kit for amplification of the membrane
glycoprotein (HCoV-229E and HCoV-OC43) or the nucleocapsid phosphopro-
tein (HCoV-HKU1 and HCoV-NL63). Each 20-l reaction mixture contained 5
l of 5 reaction buffer, 1 l of deoxynucleoside triphosphate (dNTP) (10 mM),
2 l of MgCl2 (25 mM), 0.3 l of each of the inner primers for HCoV-HKU1,
HCoV-NL63, and HCoV-OC43 (10 mM) (Table 1), 0.4 l of each inner primer
for HCoV-229E, 0.25 l of each fluorescent probe for each coronavirus (Table
1) (50 mM), and 1 l of enzyme mix. Cycling conditions were 50°C for 30 min,
95°C for 15 min, and then 50 cycles of 95°C for 30 s, 55°C for 40 s, and 72°C for
30 s. Amplified nucleic acid was detected using a Bioluminescence ABI machine.
Conventional nested PCR for coronavirus detection. Component nucleic acids
from coronavirus-positive pools were screened using reverse transcription and
nested PCR for their respective coronaviruses. This method was shown to be as
sensitive as the real-time PCR (data not shown) and was undertaken (instead of
repeated real-time PCRs) to reduce diversion of resources, a strategy that was of
particular relevance during the influenza pandemic, and also served to reduce
the cost of the reagents required to screen so many samples. Reverse transcrip-
tion was conducted using a Promega (Southampton, United Kingdom) A3500
reverse transcription system. Each 20-l reaction mixture included 4 l of MgCl2
(25 mM), 2 l of 2 reaction buffer, 2 l of dNTPs (10 mM), 1 l of random
primers (10 mM), 0.5 l of RNAsin, and 15 units of reverse transcriptase.
Reactions were conducted according to the manufacturer’s instructions, with an
extended elongation step of 55 min. Each 20-l PCR mixture contained 4 l of
MgCl2 (25 mM), 0.2 l of dNTP (3 mM), 1 l of each species-specific sense and
antisense primer (10 mM) (Table 1), and 0.4 units of Taq polymerase. The
first-round reaction mixture contained 2 l cDNA, and the second-round mix-
ture contained 1 l of the first-round product. Cycling conditions for first- and
second-round PCRs were 94°C for 21 s, the virus-specific annealing temperature
(Table 2) for 18 s, and 72°C for 90 s; cycle numbers were also virus specific (Table
2) and were followed by a hold at 72°C for 5 min. PCR products were detected
by agarose gel electrophoresis.
Coronavirus CT values. Respiratory RNA was tested for coronaviruses by
pooling RNAs in groups of 10 and screening using four-way multiplex RT-PCR.
Identification of coronavirus-positive components of coronavirus-positive RNA
pools was done using reverse transcription, nested PCR, and gel electrophoresis.
Coronavirus-positive RNA identified by the nested PCR was then retested using
the real-time RT-PCR to establish CT values for individual samples.
Statistical analyses. Statistical analyses were conducted (unless otherwise
stated) using a two-tailed Fisher’s exact test with a threshold for significance of
P  0.05, using population parameters defined by the sample set.
RESULTS
Sensitivity and specificity of four-way multiplex RT-PCR for
coronavirus detection. Serial dilutions of coronavirus RNA
transcripts were tested using the multiplex PCR. No differ-
ences in CT values were found when transcripts were tested
using single primers and probes compared to using multiplexed
primers and probes (results not shown). The fluorescent signal
observed at various dilutions for each virus type corresponded
to calculated minimal amounts of detectable RNA copy num-
bers of 66 for HCoV-229E, 9 for HCoV-HKU1, 69 for HCoV-
TABLE 1. Species-specific PCR reagents and conditions for coronavirus amplification
CoV Probea Outer sense primerb Outer antisense primerb Inner sense primera,b Inner antisense primera,b
Annealing
temp
(°C)b
No. of
PCR
cyclesb
229E FAM AAT GCA ATC ACT GTC
ACA ACC GTG
AAC CCA GCC TGT
GCT ATT TTG TG
CAT ACT ATC AAC CCA
TTC AAC AAG
CAC GGC AAC TGT
CAT GTA TT
50 35
HKU1 Cy5 ACT TCT AYT CCC TCC
GAT GTT TC
TTA TGC CTR ATT
TCC TTG GC
TCC TAC TAY TCA AGA
AGC TAT CC
AAT GAA CGA TTA
TTG GGT CCA C
52 33
NL63 TxR CCT CCT CCT TCA TTT
TAC ATG CC
ACA GAG AGC TCT
GGA GGC AA
GTT CTG ATA AGG CAC
CAT ATA GG
TTT AGG AGG CAA
ATC AAC ACG
52 30
OC43 YAK TAT GTT AGG CCG ATA
ATT GAG GAC
CCT GAT GGT TGC
TGA GAR GT
CAT ACY CTG ACG GTC
ACA ATA ATA
ACC TTA GCA ACA
GTC ATA TAA GC
52 37
a Used in real-time PCR. FAM, 6-carboxyfluorescein; YAK, Yakima Yellow.
b Used in nested PCR.
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NL63, and 18 for HCoV-OC43 in 10 l of RNA. No nonspe-
cific reactions were observed. As RNAs were pooled in groups
of 10, 1 l of each RNA was tested in the initial screening
process. Consequently, the minimum theoretical concentration
of viral RNA required for detection was likely a 10-fold in-
crease compared to the calculated values.
Detection of coronaviruses in Edinburgh and assay sensi-
tivity. All coronavirus-positive pools detected by real-time
PCR were found to include at least one coronavirus-positive
component by nested PCR. Some pools comprised samples
positive for different coronaviruses, some contained more than
one sample positive for the same coronavirus, and two samples
were found to be positive for both HCoV-OC43 and HCoV-
NL63. Of the 11,661 samples, 267 (2.30%) were positive for at
least one coronavirus (Table 2); of all virus detections, 8.15%
were of coronaviruses.
Coronavirus-positive samples detected by the nested PCR
were rescreened using real-time RT-PCR to establish CT val-
ues; of these, 86.2% (232/269) tested positive for coronavirus
by the real-time RT-PCR. In some cases, a sample that tested
as negative on rescreening represented the only coronavirus-
positive sample in its pool; therefore, these results were not
attributed to false positives in the nested PCR screening.
Patient parameters. Coronaviruses were detected in all age
groups, most frequently (4.86%) in the 7- to 12-month age
category (Fig. 1). Significantly more males (64.6%; P 0.0332)
were infected with HCoV-OC43 than females. More males
than females were infected with HCoV-NL63, but this result
TABLE 2. Detection of respiratory viruses over 3 years from 11,661 samples
Virusa
No. of samples with indicated virus(es) detectedb Detection
rate (%)AdV Flu A Flu B PIV-1 PIV-2 PIV-3 HRSV HCoV-229E HCoV-HKU1 HCoV-NL63 HCoV-OC43
AdV 783 16 3 3 2 49 119 3 3 7 17 6.7
Flu A 336 1 0 0 1 9 0 0 0 4 2.9
Flu B 131 0 0 1 0 0 0 1 0 1.1
PIV-1 75 0 1 3 0 2 0 0 0.64
PIV-2 39 0 6 0 0 0 0 0.33
PIV-3 380 11 0 2 2 1 3.3
HRSV 1,300 1 17 10 26 11.1
HCoV-229E 35 0 0 0 0.30
HCoV-HKU1 61 0 0 0.52
HCoV-NL63 75 2 0.64
HCoV-OC43 111 0.85
1 virus 565 306 125 66 32 318 1,109 31 38 57 67 23.2
2 viruses 203 29 6 9 6 59 180 4 22 14 38 4.89
3 viruses 15 1 0 0 1 3 11 0 1 4 6 0.36
a Flu A, influenza A virus; Flu B, influenza B virus.
b Boldface indicates total number of virus detections.
FIG. 1. Percentages of detection frequencies of the four coronaviruses HCoV-229E, HCoV-HKU1, HCoV-NL63, and HCoV-OC43 by age
group. The total number of samples within each age band is indicated at head of each column.
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did not reach significance (62.7%; P  0.132). HCoV-HKU1
and HCoV-229E infected approximately equal numbers of
males and females (the proportions of those infected who were
male were 50.8% and 51.4%, respectively).
Circulation trends. Coronaviruses displayed the marked
seasonality typical of other respiratory viruses, with high de-
tection frequencies in winter months but few or no detections
in the summer (Fig. 2). The exception was HCoV-229E, which
was detectable primarily in the winter of the second year of the
study and sporadically through the third year of study.
HCoV-OC43 displayed biennial peaks in detection frequen-
cy; it was present in 2.96% of samples collected in the first
season (December 2006 to April 2007), in only January of the
second season (November 2007 to March 2008) (0.83%), and
in 3.17% of samples collected in the third season (November
2008 to January 2009) (P  0.0001 for the first and third
seasons compared to the second).
For HCoV-HKU1, in contrast to the pattern described for
HCoV-OC43, the peak detection frequency occurred in the
second season (1.92% of samples collected in November 2007
to March 2008). Conversely, when HCoV-OC43 was circulat-
ing at the highest frequency, detection frequencies of HCoV-
HKU1 did not exceed 1% (P  0.0001 for the first and third
seasons compared to the second).
HCoV-NL63 was detected later than other coronaviruses in
all three seasons (in December or January), and detection
frequencies peaked in February to April. Detection frequen-
cies between seasons were more consistent than for the other
coronaviruses, although a significantly higher HCoV-NL63 de-
tection frequency was observed in the first year of study than in
the second and third years (P  0.001 and P  0.0200, respec-
tively).
Clinical associations of coronavirus infections. Clinical data
were available for 6,068/11,661 (52.0%) of samples included in
the study. Although high rates of coinfection with other respi-
ratory viruses were detected (11 to 41% of coronavirus-positive
samples tested positive for at least one other respiratory virus),
single infections associated with respiratory outcomes were
observed for three coronaviruses (HCoV-HKU1, HCoV-
NL63, and HCoV-OC43). HCoV-OC43, HCoV-NL63, and
HCoV-HKU1 had clinical profiles similar to those of respira-
tory viruses currently included in routine diagnostic screening
(Fig. 3A), with HCoV-OC43 associated with LRTI in over
40% of single infections for which clinical data were avail-
able—a higher proportion than that seen with influenza A
virus. HCoV-229E was not associated with any cases of LRTI
or URTI in otherwise healthy individuals and was found in
over 70% of cases representing samples from immunocompro-
mised patients (Fig. 3B).
Coronaviruses were not associated only with respiratory out-
comes. Febrile convulsions were not reported for any patients
testing singly positive for coronavirus, although one patient
testing singly positive for HCoV-HKU1 had meningitis and
one patient testing singly positive for HCoV-OC43 had sei-
zures. Of 35 samples testing singly positive for HCoV-OC43,
two were associated with vomiting, though one of these was
taken from an immunocompromised patient.
Croup has previously been associated with HCoV-NL63 in-
fection (19, 33, 37) but was not reported in association with any
of the 41 samples with clinical data testing singly positive for
HCoV-NL63; 3 samples were associated with cough and 1 was
associated with wheezing.
For children under 2 years of age with LRTI, coronaviruses
represented the only virus detected in 20 of 916 (2.18%) sam-
ples, compared with a rate of 5 of 336 (1.49%) samples col-
lected from patients over the age of 45 with LRTI. The differ-
ence was not significant (P  0.5).
For all four coronaviruses combined, the detection fre-
quency in samples from patients with respiratory symptoms
(URTI and LRTI) exceeded the proportion seen with samples
taken from patients whose symptoms were categorized as
“none” (i.e., no respiratory symptoms; Fig. 3C), providing ep-
idemiologic evidence for the role of these three viruses in the
etiology of respiratory disease.
No differences were found between the CT values of coro-
navirus-positive samples associated with differing respiratory
outcomes (data not shown).
Coinfections. High rates of coinfection with other respira-
tory viruses were observed for all coronaviruses (Table 2).
Similar rates of LRTI and URTI were observed in single coro-
FIG. 2. Coronavirus and influenza virus (A and B combined) detection frequencies by month over the 3 years of the study.
VOL. 48, 2010 CORONAVIRUS EPIDEMIOLOGY AND CLINICAL SIGNIFICANCE 2943
FIG. 3. (A) Comparison of the clinical presentations of study subjects infected with coronaviruses to the clinical presentations of those infected
with respiratory viruses included in diagnostic screening (adenovirus [AdV], influenza A virus, influenza B virus, PIV-1, PIV-2, PIV-3, and HRSV).
Only single infections are included in the analysis. The y axis indicates proportions of subjects with symptoms or diagnoses of LRTI or URTI or
symptoms not associated with respiratory infection (“None”). (B) Proportions of samples testing singly positive for each of the respiratory viruses
from patients with immunosuppression. (C) Proportions of samples from patients with LRTI or URTI or with no respiratory symptoms (“None”)
testing singly positive for each respiratory virus.
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navirus infections (HcoV-HKU1 and HCoV-OC43) compared
to cases in which a coronavirus was detected as part of a mixed
infection. LRTI and URTI were observed at a higher fre-
quency in single compared to mixed infections with HCoV-
NL63 (Table 3).
Of all samples testing positive for coronavirus and another
respiratory virus, 63.5% tested positive for HRSV. Coronavi-
rus infection seasonality most closely resembles that of influ-
enza (Fig. 2), and so the coinfection frequency of HRSV with
coronaviruses is compared to the coinfection frequency of
HRSV with influenza virus. Of 1,300 HRSV-positive samples,
only 9 (0.682%) tested positive for influenza A or influenza B
virus, whereas 54 (4.15%) tested positive for coronavirus (P 
0.0001, based on the assumption that influenza virus and coro-
naviruses have the same seasonality).
Samples from patients testing positive for a routine virus
were more likely to have LRTI when coronavirus was also
detected (52.2% compared to 43.2%), though this result did
not reach significance (P  0.231).
CT values were available for most coronavirus-positive sam-
ples (229/286; Table 4). Few differences in CT value were
observed between singly infected coronavirus-positive samples
and coronavirus-positive samples also testing positive for an-
other virus (Table 4).
DISCUSSION
Human coronaviruses are increasingly recognized as respi-
ratory pathogens associated with a broadening range of clinical
outcomes, whereas they were once recognized as “common
cold” viruses. Here we demonstrate that HCoV-OC43, HCoV-
NL63, and HCoV-HKU1 were specifically associated with
lower respiratory tract disease in the study population. Three
of the four coronaviruses were more frequently detected as the
sole pathogen in subjects with LRTI than in those with no
respiratory symptoms and were detected as often as PIV-1 and
PIV-2 (Fig. 3A). Samples representing monoinfections were
frequently (26/184 [14.1%]) from subjects in intensive care
and/or high-dependency units, with presentations that included
severe lower respiratory tract disease and pyrexia, and case
reports have associated all coronaviruses with high morbidity
and/or fatal outcomes (23, 25, 26, 34).
HCoV-OC43 was the most commonly detected coronavirus,
followed by HCoV-NL63 and HCoV-HKU1, with similar mod-
erate detection frequencies, and HCoV-229E, with a compar-
atively low detection frequency; this observation has been pre-
viously reported (18). However, in contrast to the results of a
previous study (18), we found that HCoV-HKU1 was detected
as frequently in patients with LRTI as in those with URTI, and
there was a lack of association between HCoV-229E infection
and respiratory symptoms in otherwise healthy individuals.
HCoV-NL63 detection peaked in winter and spring (January
to April), which contrasts with the summer-to-autumn season-
ality reported to occur in the tropics (4, 18), though the au-
tumn-to-winter seasonality of HCoV-HKU1 and HCoV-OC43
infections and lack of a discernible seasonality of HCoV-229E
infections were epidemiologically comparable features of both
regions.
In 42% and 38% of infections with HCoV-OC43 and HCoV-
HKU1, other respiratory viruses were codetected, most com-
monly HRSV. There were significantly more HRSV-positive
samples that tested positive for coronavirus compared to the
numbers of samples testing negative for all viruses included in
routine diagnostics (one-tailed test; P  1.34  105). The
high rate of coinfection of coronaviruses with HRSV observed
here was previously demonstrated (17). No differences in clin-
ical outcome were observed for those coinfected with HRSV
and coronavirus compared with those singly infected with ei-
ther virus, and so HRSV presumably facilitates coronavirus
infections (or vice versa) without exacerbating morbidity.
HCoV-OC43 was significantly more frequently detected in
hospitalized males than in females, an attribute that HCoV-
OC43 shares with HRSV (8, 21, 24). No difference was ob-
served between the sex distribution of HCoV-OC43 in singly
infected subjects and the sex distribution in those coinfected
with HRSV, indicating that the observed sex bias was coinci-
dental and is not attributable to high coinfection rates.
The coronavirus load in singly positive samples was not
different from the coronavirus load in samples in which co-
pathogens were detected. This suggests that infection with
another respiratory virus does not affect the ability of corona-
viruses to establish infection and further demonstrates that, in
mixed infections in respiratory patients, detection of corona-
viruses should not be interpreted as representing an incidental
infection that does not contribute to disease.
HCoV-229E differed clinically from other coronaviruses and
TABLE 3. Detection frequencies of coronavirus cases of
LRTI and URTI
Clinical
outcome
Detection frequency (%)
HCoV-229E
(all)
HCoV-HKU1 HCoV-NL63 HCoV-OC43
Single Mixed Single Mixed Single Mixed
LRTI 0 4 5 12 3 13 16
URTI 0 3 1 6 1 2 0
TABLE 4. Coronavirus CT values for singly infected and coinfected samples
CoV CT
value
No. of samples with indicated result
HCoV-229E HCoV-HKU1 HCoV-NL63 HCoV-OC43
Single
infection Coinfection
Single
infection Coinfection
Single
infection Coinfection
Single
infection Coinfection
30 15 3 6 6 1 0 7 3
30–35 15 1 19 8 19 4 31 13
35 0 0 2 1 33 9 22 14
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other respiratory viruses in general; 70% of detections were in
samples from immunocompromised patients. HCoV-229E has
previously been associated with infections of immunocompro-
mised individuals (9, 26). The further association of HCoV-
NL63 with this group was previously suggested in a report of a
smaller epidemiologic study (9) and in a case report (23).
Evidence indicating the role of these coronaviruses in disease
etiology in immunocompromised individuals increasingly
points to the conclusion that detection of infections by these
viruses should be considered to require alternative diagnoses
for immunocompromised individuals with respiratory tract
symptoms.
Most individuals seroconvert for HCoV-229E, HCoV-NL63,
and HCoV-OC43 in childhood (5, 13, 15, 20). No cell culture
system is currently available for HCoV-HKU1 analyses, and so
seroprevalence studies rely on alternative techniques (1). Re-
infection with coronaviruses HCoV-229E and HCoV-OC43 is
a common occurrence (22). Epidemiologically, HCoV-NL63
and HCoV-HKU1 were similar to other coronaviruses in that
they were detected in all age groups and equally frequently,
and so it is likely that HCoV-HKU1 and HCoV-NL63 cause
repeated infections throughout life also.
Human coronaviruses divide serologically into two groups,
though the extent of serologic cross-reactivity within and be-
tween groups is mostly evaluated in comparison with severe
acute respiratory syndrome (SARS)-associated coronavirus in-
fections (2, 3, 25, 36). Coronaviruses may independently fluc-
tuate in circulation rates, or epidemiologic interference within
or between Alphacoronavirinae (HCoV-229E and HCoV-
NL63) and Betacoronavirinae (HCoV-HKU1 and HCoV-
OC43) species may occur. HCoV-HKU1, HCoV-NL63, and
HCoV-OC43 all significantly differed in detection frequen-
cies throughout the study period, and variability in the de-
tection frequency of HCoV-229E has been previously re-
ported (9, 12, 20).
Development of a novel pan-coronavirus multiplex PCR al-
lows unique insights into the epidemiology and clinical impli-
cations of infections by the four respiratory coronaviruses.
Fluctuating circulation frequencies of coronaviruses between
respiratory seasons are reported here for the first time. All
coronaviruses are associated with high coinfection rates, and
detection of HCoV-229E infection should be particularly con-
sidered for an alternative diagnosis for immunocompromised
patients with respiratory tract disease.
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